VIVUS Inc. (VVUS)

4.32
NASDAQ : Health Technology
Prev Close 3.98
Day Low/High 3.77 / 4.32
52 Wk Low/High 2.15 / 6.41
Avg Volume 80.30K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 42.36M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Vivus Shares Soar; FDA Panel Recommends Qnexa Approval

Vivus Shares Soar; FDA Panel Recommends Qnexa Approval

The stock nearly doubles after an advisory committee says the obesity drug should be granted marketing approval.

Vivus: FDA Panel Live Blog

Vivus: FDA Panel Live Blog

TheStreet's biotech columnist Adam Feuerstein is providing live coverage of the FDA advisory panel reviewing Vivus' obesity pill Qnexa.

Wednesday's Top 10 Articles, Videos on TheStreet

Wednesday's Top 10 Articles, Videos on TheStreet

These stories made today's top 10 list of articles and videos on TheStreet.

A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer'

A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer'

An analysis of experts' past voting records shows Vivus faces a stiff test Wednesday from an FDA panel reviewing the obesity drug Qnexa.

Fitz Bits: Scoop Up Intel Shares

Fitz Bits: Scoop Up Intel Shares

Intel is attracting institutional buyers, and it always pays to follow that crowd.

Business Highlights

Business Highlights

Business Highlights

Friday's Top 10 Articles, Videos on TheStreet

Friday's Top 10 Articles, Videos on TheStreet

These stories made today's top 10 list of articles and videos on TheStreet.

8 Stocks Rising on Monster Volume

8 Stocks Rising on Monster Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

NRC OKs Exelon Takeover of Constellation: Hot Trends

NRC OKs Exelon Takeover of Constellation: Hot Trends

The Nuclear Regulatory Commission approves Exelon's proposed $7.9 billion takeover of Constellation Energy.

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

These Drugs Stocks Will Win FDA Approval

These Drugs Stocks Will Win FDA Approval

Contestants in TheStreet's FDA Drug-Approval Contest forecast their winners and losers.

8 Stocks Hitting New 52-Week Highs

8 Stocks Hitting New 52-Week Highs

When a stock is hitting new 52-week highs, it often means that the uptrend is very strong and the buyers are in full control.

Play TheStreet's FDA Drug-Approval Contest

Play TheStreet's FDA Drug-Approval Contest

The FDA will issue approval decisions on 17 drugs over the next four months. How well can you predict which drugs will be approved or rejected?

Biotech Lessons Learned From JPM 2012

Biotech Lessons Learned From JPM 2012

Biotech stocks got off to a ripping start at the most closely watched healthcare conference of the year.

8 Stocks Rising on Unusual Volume

8 Stocks Rising on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

J.P. Morgan Biotech Confab Live Chat

J.P. Morgan Biotech Confab Live Chat

TheStreet's Adam Feuerstein will give his impressions of the J.P. Morgan Healthcare Conference and answer readers' biotech investing questions.

6 Stocks Rising on Huge Volume

6 Stocks Rising on Huge Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Biotech 2012 Kickoff Party: Investor Preview

Biotech 2012 Kickoff Party: Investor Preview

What every biotech investor needs to know before next week's J.P. Morgan Healthcare Conference.

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Into Vivus, Inc.

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Into Vivus, Inc.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Vivus, Inc.

Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

FDA and an outside panel of experts will decide whether the risk of cleft lips and palates is acceptable or too high for Vivus' Qnexa to be approved.

Market Preview: Staving Off the Grinch

Market Preview: Staving Off the Grinch

A third straight drop in weekly jobless claims would be a boon for the bulls. In the video, Chao Deng recaps the trading action.

27 Hot Drugs Facing FDA Approval in 2012

27 Hot Drugs Facing FDA Approval in 2012

These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.

22 Hot Drugs Facing FDA Approval in 2012

22 Hot Drugs Facing FDA Approval in 2012

These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.

Biotech Stock Mailbag: Ariad, Amarin, Arena

Biotech Stock Mailbag: Ariad, Amarin, Arena

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

10 Most Shorted Stocks in Biotech

10 Most Shorted Stocks in Biotech

Short-sellers are taking aim at Savient, Avanir Pharma and other biotech firms launching new drugs in a challenging economy.

Orexigen: Contrave's Odds Still Slim

Orexigen: Contrave's Odds Still Slim

Orexigen is back in business with its obesity pill but the risk and challenges ahead are still daunting and approval is far from assured.

Adobe, Orexigen: After-Hours Trading

Adobe, Orexigen: After-Hours Trading

The big movers after Tuesday's closing bell included Adobe Systems, Orexigen Therapeutics, and Oracle.

Orexigen Resurrects Rejected Obesity Drug

Orexigen Resurrects Rejected Obesity Drug

An agreement with FDA for a shorter safety study allows Orexigen to restart development of its obesity drug Contrave.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look poised to break out and trade higher from current prices.

Biotech Stock Mailbag: Vivus

Biotech Stock Mailbag: Vivus

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

TheStreet Quant Rating: D (Sell)